Sugi Predict

Sugi Predict / Compounds / SCHEMBL2994007

SCHEMBL2994007

SCHEMBL2994007

C[N+](C)(C)CC(CC(=O)[O-])ON

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 3/20 0.65
▸ KMT2A Q03164 3/20 0.65
▸ CYP1A2 P05177 1/20 0.65
▸ HRH1 P35367 1/20 0.65
▸ CYP2C19 P33261 2/20 0.61
▸ RECQL P46063 1/20 0.61
▸ CPT2 P23786 1/20 0.57
▸ CPT1A P50416 1/20 0.57
▸ SLC22A16 Q86VW1 1/20 0.55
▸ SLC25A20 O43772 3/20 0.51
▸ TSHR P16473 3/20 0.51
▸ TP53 P04637 2/20 0.51
▸ CYP2D6 P10635 2/20 0.51
▸ SLC6A5 Q9Y345 2/20 0.51
▸ CYP2C9 P11712 2/20 0.51
▸ KDM4E B2RXH2 1/20 0.51
▸ CYP3A4 P08684 1/20 0.51
▸ MAPT P10636 1/20 0.51
▸ NFKB1 P19838 1/20 0.51
▸ THPO P40225 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phosphine SCHEMBL27625263 0.98 MEN1 (0.62) MEN1KMT2ACYP1A2HRH1CYP2C19
Hydrochloric Acid SCHEMBL7881495 0.98 MEN1 (0.62) MEN1KMT2ACYP1A2HRH1CYP2C19
Hydrochloric Acid SCHEMBL9504223 0.98 MEN1 (0.62) MEN1KMT2ACYP1A2HRH1CYP2C19
SCHEMBL28171779 0.86 MEN1 (0.67) MEN1KMT2ACYP1A2HRH1CYP2C19
SCHEMBL4256715 0.85 MEN1 (0.71) MEN1KMT2ACYP1A2HRH1CYP2C19
SCHEMBL1208087 0.85 MEN1 (0.71) MEN1KMT2ACYP1A2HRH1CYP2C19
SCHEMBL17629809 0.85 MEN1 (0.71) MEN1KMT2ACYP1A2HRH1CYP2C19
SCHEMBL27645614 0.82 LMNA (0.61) MEN1KMT2ACYP1A2HRH1CYP2C19
SCHEMBL7031982 0.82 MEN1 (0.67) MEN1KMT2ACYP1A2HRH1CYP2C19
Hydrochloric Acid SCHEMBL28029014 0.80 MEN1 (0.65) MEN1KMT2ACYP1A2HRH1CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102159080-A Enzyme inhibitors and the use thereof DARA BIOSCIENCES INC 2011-08-17 — — CN claimed
CN-1735588-B Synthesis for (R) and (S)-aminocarnitine and derivatives thereof from D-and L-aspartic acid SIGMA TAU IND FARMACEUTI 2010-05-26 — — CN claimed
CN-101511780-A 4-trimethylammonium-3-aminobutyrate and 4-trimethyl  -3-aminobutyrate derivatives as CPT-inhibitors SIGMA TAU IND FARMACEUTI (IT) 2009-08-19 — — CN claimed
CN-1735588-A Synthesis for (R) and (S)-aminocarnitine and derivatives thereof from D-and L-aspartic acid SIGMA TAU IND FARMACEUTI (IT) 2006-02-15 — — CN claimed
CN-1231460-C Process for the preparation of (R)-or (S)-aminocarnitine inner salt, the salts and derivatives thereof SIGMA TAU IND FARMACEUTI (IT) 2005-12-14 — — CN claimed
CN-1527811-A Process for preparing -or (S) -aminocarnitine inner salt, and salts and derivatives thereof ϣ��������ҩ��ҵ��˾ 2004-09-08 — — CN claimed
EP-0177574-A4 AMINOCARNITINES. CORNELL RES FOUNDATION INC (US) 1987-08-03 — — EP claimed
EP-0177574-A1 AMINOCARNITINES. CORNELL RES FOUNDATION INC (US) 1986-04-16 — — EP claimed
WO-1985004396-A1 AMINOCARNITINES CORNELL RESEARCH FOUNDATION, INC. (US) 1985-10-10 — — WO claimed
US-10130602-B2 Use of L-carnitine, salts and derivatives thereof for reducing or preventing fatigue and improving cognitive function LONZA LTD. (CH) 2018-11-20 — — US disclosed
US-20160166532-A1 CARNITINE PALMITOYLTRANSFERASE 1 INHIBITORS FOR INHIBITION OF PATHOLOGICAL ANGIOGENESIS LIFE SCIENCES RESEARCH PARTNERS VZW (BE) 2016-06-16 — — US disclosed
US-20150150770-A1 METHODS OF TREATING SKIN TRACIE MARTYN INTERNATIONAL INC (US) 2015-06-04 — — US disclosed
CN-104125848-A Use of CPT-1 modulators and compositions thereof AVON PROD INC 2014-10-29 — — CN disclosed
US-20140155961-A1 METHODS OF TREATING SKIN Tracie Martyn International, Inc. (US) 2014-06-05 — — US disclosed
US-4866040-A DRUG COVALENTLY BONDED TO AMINOCARNITINE FOR DELIVERY TO SPECI FIC SITES CEPTOR CORPORATION 1989-09-12 — — US disclosed
US-4781863-A FROM 6-CHLOROMETHYLURACIL CORNELL RESEARCH FOUNDATION, INC. (US) 1988-11-01 — — US disclosed
EP-0279887-A2 Carnitine directed pharmaceutical agents and their use for the manufacture of a medicament for the treatment of muscle disorder Stracher, Alfred (US) 1988-08-31 — — EP disclosed
EP-0177574-A4 AMINOCARNITINES. CORNELL RES FOUNDATION INC (US) 1987-08-03 — — EP disclosed
EP-0177574-A1 AMINOCARNITINES. CORNELL RES FOUNDATION INC (US) 1986-04-16 — — EP disclosed
WO-1985004396-A1 AMINOCARNITINES CORNELL RESEARCH FOUNDATION, INC. (US) 1985-10-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140155961-A1 METHODS OF TREATING SKIN CUTA, LIPA, DLAT MEN1 4283/4885KMT2A 2256/4885CYP1A2 3948/4885
US-20150150770-A1 METHODS OF TREATING SKIN CUTA, LIPA, DLAT MEN1 4283/4885KMT2A 2256/4885CYP1A2 3948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.